Phase 2 Clinical Trial Enrolls 705 Patients

Johnson & Johnson (JNJ), through its subsidiary Intra-Cellular Therapies, is currently enrolling patients in a Phase 2 clinical trial (NCT06480383) evaluating ITI-1284, a potential adjunctive therapy for Generalized Anxiety Disorder (GAD). As of the January 2026 update, the target enrollment is 705 patients, with the study being conducted across the United States, Bulgaria, Czech Republic, Finland, Poland, and Serbia. The trial commenced on August 5, 2024, with a primary completion date and overall study completion date projected for June 2027, indicating a focus on accumulating mid-term data rather than short-term clinical events.

Designed for Patients with Insufficient Response

The study design involves a randomized, 1:1:1 allocation of adult patients with GAD who have not responded adequately to existing treatments, receiving either ITI-1284 at 10mg, 20mg, or a placebo. The trial structure includes a maximum 3-week screening period, a 6-week double-blind treatment period, and a 1-week safety follow-up, allowing for the simultaneous evaluation of efficacy, safety, and tolerability. The strategy of adding ITI-1284 to existing Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) aims to reduce the burden of switching to monotherapy and directly targets a patient population that is relevant in real-world clinical practice.

Differentiation Through Deuterated Lumateperone

ITI-1284, also known as deulumateperone, is a deuterated form of lumateperone, currently being developed under the code name ITI-1284 ODT-SL. It is being developed as a sublingual oral disintegrating tablet and, like its parent drug, utilizes a multi-pharmacological approach, including serotonin 5-HT2A receptor antagonism, dopamine D2 receptor modulation, and serotonin transporter inhibition. Deuteration is a medicinal chemistry strategy aimed at modifying metabolic properties; however, the clinical efficacy and tolerability advantages in GAD need to be demonstrated in this Phase 2 data.

Competition with Standard Treatments and Later-Stage Pipeline Assets

The current standard of care includes Lexapro (escitalopram), Cymbalta (duloxetine), Effexor XR (venlafaxine), Buspar (buspirone), and benzodiazepines. A key competitor in the clinical landscape is MM120 (lysergide) from Mind Medicine (MNMD), which is in Phase 3 development for GAD, placing it at a later stage than ITI-1284. In 2024, the GAD market across the top 7 major markets was estimated at USD 1.71 billion and is projected to reach USD 2.90 billion in 2034. Therefore, ITI-1284 needs to demonstrate both superior efficacy and safety compared to generic alternatives to secure a commercial premium.

J&J Acquisition Combines Capital and Commercialization Capabilities

J&J completed the acquisition of Intra-Cellular Therapies on April 2, 2025, for USD 132 per share, totaling approximately USD 14.6 billion in cash. Existing ITCI shares have ceased trading on the Nasdaq. CAPLYTA (lumateperone), which was acquired as part of the deal, has been approved by the FDA for schizophrenia on December 20, 2019, for bipolar depression on December 17, 2021, and as an adjunctive therapy for major depressive disorder on November 6, 2025. ITI-1284 is a pre-approval Phase 2 asset, and the data expected in 2027 will be a key value inflection point for J&J, demonstrating whether it can extend its stated neuroscience growth strategy to GAD.